Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1903-1912

  Joel, S P ^a   Ellis, P ^a   O'Byrne, K ^a   Papamichael, D ^a   Hall, M ^a   Penson, R ^a   Nicholls, S ^a   O'Donnell, C ^a   Constantinou, A ^a   Woodhull, J ^a   Nicholson, M ^a   Smith, I ^a   Talbot, D ^a   Slevin, M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL;

EID: 8944246796     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1903     Document Type: Article

References (36)

1. Belani C, Doyle L, Aisner J: Etoposide: Current status and future perspectives in the management of malignant neoplasms. Cancer Chemother Pharmacol 34:118-127, 1994
2. Hill BT, Whelan RD, Rupniak HT, et al: A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or microfluorimetry. Cancer Chemother Pharmacol 7:21-26, 1981
3. Drewinko B, Barlogie B: Survival and cell-cycle progression delay of human lymphoma cells in vitro exposed to VP16-213. Cancer Treat Rep 60:1295-1306, 1976
4. Dombernofsky P, Nissen N: Schedule dependency of the antileukaemic activity of the podophyllotoxin-derivative VP16-213 in L1210 leukaemia. Acta Pathol Microbiol Scand [A] 81:715-724, 1973
5. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
6. Clark PI, Slevin ML, Joel SP, et al: A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427-1435, 1994
7. Abratt RP, Willcox PA, deGroot M, et al: Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur J Cancer 27:28-30, 1991
8. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
9. Sessa C, Zucchetti M, Torri V, et al: Chronic oral etoposide in small-cell lung cancer: Clinical and pharmacokinetic results. Ann Oncol 4:553-558, 1993
10. Clark PI, Cottier B: The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 19:36-39, 1992
11. Slevin ML, Joel SP: Prolonged oral etoposide in small cell lung cancer. Ann Oncol 4:529-532, 1993 (editorial)
12. Miller AA, Herndon JE, Hollis DR, et al: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13:1871-1879, 1995
13. Joel SP, Dolega-Ossowski E, Jones K, et al: The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc Annu Meet Am Assoc Cancer Res 32:178, 1991 (abstr)
14. Harvey VJ, Slevin ML, Joel SP, et al: Variable bioavailability following repeated oral doses of etoposide. Eur J Cancer Clin Oncol 21:1315-1319, 1985
15. Slevin ML, Joel SP, Whomsley R, et al: The effect of dose on the bioavailability of oral etoposide: Confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 24:329-331, 1989
16. Hande KR, Krozely MG, Greco FA, et al: Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374-377, 1993
17. Ratain MJ, Mick R, Schilsky RL, et al: Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity. J Clin Oncol 9:1480-1486, 1991
18. Thompson DS, Hainsworth JD, Hande KR, et al: Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study. Cancer 73:2824-2831, 1994
19. Minami H, Shimokata K, Saka H, et al: Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 11:1602-1608, 1993
20. Joel S, Clark P, Slevin M: Stability of the IV and oral formulations of etoposide in solution. Cancer Chemother Pharmacol 37:117-124, 1995
21. Common toxicity criteria, in Investigators Handbook. A Manual for Participants in Clinical Trials of Investigational New Agents. NIH Pub 93:2770, 1993
22. Harvey VJ, Joel SP, Johnston A, et al: High-performance liquid chromatography of etoposide in plasma and urine. J Chromatogr 339:419-423, 1985
23. Stewart CF, Fleming RA, Arbuck SG, et al: Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer Res 50:6854-6856, 1990
24. Kaplan ER, Meier P: Non-parametric estimation from incomplete observations. Am Stat Assoc 53:457-481, 1958
25. Peto R, Pike MC, Armitage P: Design and analysis of clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
26. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
27. Miller AA, Stewart CF, Tolley EA: Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 25:361-366, 1990
28. Joel S, Shah R, Clark P, et al: Predicting etoposide toxicity: Relationship to organ function and protein binding. J Clin Oncol 14:257-267, 1996
29. Grochow LB, Baraldi C, Noe D: Is dose normalisation to weight or body surface area useful in adults? JNCI 82:323-325, 1990
30. Stewart CF, Arbuck SG, Fleming RA, et al: Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Ther 50:385-393, 1991
31. Aisner J, Van Echo D, Whiteacre M, et al: A phase I trial of continuous infusion VP16-213 (etoposide). Cancer Chemother Pharmacol 7:157-160, 1982
32. Wolff SN, Grosh WW, Prater K, et al: In vitro pharmacodynamic evaluation of VP16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 19:246-249, 1987
33. Matsushima Y, Kanzawa F, Hoshi A, et al: Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14:104-107, 1985
34. Markovits J, Pommier Y, Kerrigan D, et al: Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47:2050-2055, 1987
35. Wang LM, Capizzi RL: Pharmacologic synergy between arac and inhibitors of topoisomerase II (topo II). Proc Am Assoc Cancer Res 31:437, 1990 (abstr)
36. Greco F, Hainsworth J: Prolonged administration of low daily dose etoposide: A superior dosing schedule? Cancer Chemother Pharmacol 34:101-104, 1994